131 related articles for article (PubMed ID: 23809512)
1. Renal effects of NO-inhibition in patients with cirrhosis vs. healthy controls: a randomized placebo-controlled crossover study.
Bech JN; Aagaard NK; Pedersen RS; Sorensen TB; Vilstrup H; Pedersen EB
Liver Int; 2014 Feb; 34(2):211-9. PubMed ID: 23809512
[TBL] [Abstract][Full Text] [Related]
2. Effects of systemic NO synthesis inhibition on RPF, GFR, UNa, and vasoactive hormones in healthy humans.
Bech JN; Nielsen CB; Pedersen EB
Am J Physiol; 1996 May; 270(5 Pt 2):F845-51. PubMed ID: 8928847
[TBL] [Abstract][Full Text] [Related]
3. Enhanced sodium retention after acute nitric oxide blockade in mildly sodium loaded patients with essential hypertension.
Bech JN; Nielsen EH; Pedersen RS; Svendsen KB; Pedersen EB
Am J Hypertens; 2007 Mar; 20(3):287-95. PubMed ID: 17324742
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis.
La Villa G; Barletta G; Pantaleo P; Del Bene R; Vizzutti F; Vecchiarino S; Masini E; Perfetto F; Tarquini R; Gentilini P; Laffi G
Hepatology; 2001 Jul; 34(1):19-27. PubMed ID: 11431729
[TBL] [Abstract][Full Text] [Related]
5. Dietary sodium affects systemic and renal hemodynamic response to NO inhibition in healthy humans.
Bech JN; Nielsen CB; Ivarsen P; Jensen KT; Pedersen EB
Am J Physiol; 1998 May; 274(5):F914-23. PubMed ID: 9612329
[TBL] [Abstract][Full Text] [Related]
6. Renal and hormonal effects of systemic nitric oxide inhibition in patients with congestive heart failure and in healthy control subjects.
Bech JN; Starklint J; Bentzen H; Nyvad O; Pedersen EB
J Card Fail; 2013 Nov; 19(11):776-85. PubMed ID: 24263123
[TBL] [Abstract][Full Text] [Related]
7. Nitric oxide synthase inhibition does not improve renal function in cirrhotic patients with ascites.
Thiesson HC; Skøtt O; Jespersen B; Schaffalitzky de Muckadell OB
Am J Gastroenterol; 2003 Jan; 98(1):180-6. PubMed ID: 12526955
[TBL] [Abstract][Full Text] [Related]
8. Changes in renal and systemic hemodynamics after NO-synthase inhibition in males with family history of hypertension.
Berger ED; Bader BD; Rüb N; Rauscher MA; Rebenschütz I; Gaber OC; Enderle MD; Risler T; Erley CM
Kidney Blood Press Res; 2002; 25(1):42-9. PubMed ID: 11834876
[TBL] [Abstract][Full Text] [Related]
9. Effect of nebivolol on renal nitric oxide availability and tubular function in patients with essential hypertension.
Mose FH; Jensen JM; Therwani S; Mortensen J; Hansen AB; Bech JN; Pedersen EB
Br J Clin Pharmacol; 2015 Sep; 80(3):425-35. PubMed ID: 25778445
[TBL] [Abstract][Full Text] [Related]
10. The systemic and renal response to NO inhibition is not modified by angiotensin-II-receptor blockade in healthy humans.
Bech JN; Svendsen KB; Nielsen CB; Pedersen EB
Nephrol Dial Transplant; 1999 Mar; 14(3):641-7. PubMed ID: 10193813
[TBL] [Abstract][Full Text] [Related]
11. Acute effects of nitric oxide synthase inhibition on systemic, hepatic, and renal hemodynamics in patients with cirrhosis and ascites.
Spahr L; Martin PY; Giostra E; Niederberger M; Lang U; Capponi A; Hadengue A
J Investig Med; 2002 Mar; 50(2):116-24. PubMed ID: 11928940
[TBL] [Abstract][Full Text] [Related]
12. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
[TBL] [Abstract][Full Text] [Related]
13. The renal and systemic hemodynamic effects of a nitric oxide-synthase inhibitor are reversed by a selective endothelin(a) receptor antagonist in men.
Schmidt A; Bayerle-Eder M; Pleiner H; Zeisner C; Wolzt M; Mayer G; Schmetterer L
Nitric Oxide; 2001 Aug; 5(4):370-6. PubMed ID: 11485375
[TBL] [Abstract][Full Text] [Related]
14. Effect of nitric oxide inhibition on blood pressure and renal sodium handling: a dose-response study in healthy man.
Larsen T; Mose FH; Bech JN; Pedersen EB
Clin Exp Hypertens; 2012; 34(8):567-74. PubMed ID: 22559218
[TBL] [Abstract][Full Text] [Related]
15. Assessment of endothelial function of the renal vasculature in human subjects.
Delles C; Jacobi J; Schlaich MP; John S; Schmieder RE
Am J Hypertens; 2002 Jan; 15(1 Pt 1):3-9. PubMed ID: 11824856
[TBL] [Abstract][Full Text] [Related]
16. Exaggerated natriuresis during clamping of systemic NO supply in healthy young men.
Simonsen JA; Rasmussen MS; Vach W; Høilund-Carlsen PF; Bie P
Clin Sci (Lond); 2012 Jan; 122(2):63-73. PubMed ID: 21749320
[TBL] [Abstract][Full Text] [Related]
17. Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study.
Al Therwani S; Malmberg MES; Rosenbaek JB; Bech JN; Pedersen EB
BMC Nephrol; 2017 Aug; 18(1):268. PubMed ID: 28810844
[TBL] [Abstract][Full Text] [Related]
18. Physiological role of nitric oxide in regulation of renal function in humans.
Haynes WG; Hand MF; Dockrell ME; Eadington DW; Lee MR; Hussein Z; Benjamin N; Webb DJ
Am J Physiol; 1997 Mar; 272(3 Pt 2):F364-71. PubMed ID: 9087680
[TBL] [Abstract][Full Text] [Related]
19. Effects of nitric oxide synthase inhibition and L-arginine on renal haemodynamics in young patients at high cardiovascular risk.
Schlaich MP; Oehmer S; Schneider MP; Delles C; Schmidt BM; Schmieder RE
Atherosclerosis; 2007 May; 192(1):155-60. PubMed ID: 16765359
[TBL] [Abstract][Full Text] [Related]
20. Impact of the endothelial nitric oxide synthase gene G894T polymorphism on renal endothelial function in patients with type 2 diabetes.
Ritt M; Ott C; Delles C; Schneider MP; Schmieder RE
Pharmacogenet Genomics; 2008 Aug; 18(8):699-707. PubMed ID: 18622262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
